During the recent session, Abbott Laboratories (NYSE:ABT)’s traded shares were 1.8 million, with the beta value of the company hitting 0.74. At the last check today, the stock’s price was $124.90, reflecting an intraday gain of 1.36% or $1.68. The 52-week high for the ABT share is $123.23, that puts it up 1.34 from that peak though still a striking 20.17% gain since the share price plummeted to a 52-week low of $99.71. The company’s market capitalization is $216.63B, and the average intraday trading volume over the past 10 days was 7.13 million shares, and the average trade volume was 5.33 million shares over the past three months.
Abbott Laboratories (ABT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.77. ABT has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 12 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.06.
Abbott Laboratories (NYSE:ABT) trade information
Abbott Laboratories (ABT) registered a 1.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.36% in intraday trading to $124.90, hitting a weekly high. The stock’s 5-day price performance is 9.65%, and it has moved by 9.34% in 30 days. Based on these gigs, the overall price performance for the year is 9.56%. The short interest in Abbott Laboratories (NYSE:ABT) is 14.32 million shares and it means that shorts have 3.01 day(s) to cover.
The consensus price target of analysts on Wall Street is $129, which implies an increase of 3.18% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24.01 and $139 respectively. As a result, ABT is trading at a discount of -11.29% off the target high and 80.78% off the low.
Abbott Laboratories (ABT) estimates and forecasts
Statistics show that Abbott Laboratories has underperformed its competitors in share price, compared to the industry in which it operates. Abbott Laboratories (ABT) shares have gone up 16.45% during the last six months, with a year-to-date growth rate less than the industry average at 10.28% against 11.80. In the rating firms’ projections, revenue will increase 5.83% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.38B as predicted by 20 analyst(s). Meanwhile, a consensus of 20 analyst(s) estimates revenue growth to 10.94B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.96B and 10.38B respectively. In this case, analysts expect current quarter sales to grow by 4.18% and then jump by 5.45% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 30.08%. While earnings are projected to return 10.35% in 2025, the next five years will return 8.15% per annum.
ABT Dividends
Abbott Laboratories is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Abbott Laboratories is 2.24, with the dividend yield indicating at 1.79 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 1.66%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Abbott Laboratories insiders own 0.53% of total outstanding shares while institutional holders control 77.55%, with the float percentage being 77.97%. VANGUARD GROUP INC is the largest shareholder of the company, while 3591.0 institutions own stock in it. As of 2024-06-30, the company held over 166.35 million shares (or 9.5932% of all shares), a total value of $17.29 billion in shares.
The next largest institutional holding, with 131.13 million shares, is of BLACKROCK INC.’s that is approximately 7.5619% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $13.63 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Abbott Laboratories (ABT) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 55.15 shares. This amounts to just over 3.18 percent of the company’s overall shares, with a $6.88 billion market value. The same data shows that the other fund manager holds slightly less at 45.57, or about 2.63% of the stock, which is worth about $5.69 billion.
